T 1152/21 of 24.06.2024
- European Case Law Identifier
- ECLI:EP:BA:2024:T115221.20240624
- Date of decision
- 24 June 2024
- Case number
- T 1152/21
- Petition for review of
- -
- Application number
- 14705884.6
- IPC class
- A61K 31/519C07D 471/04A61P 35/00
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- Abstract on EPC2000 Art 084
- Application title
- SOLID FORMS OF A SELECTIVE CDK4/6 INHIBITOR
- Applicant name
- Pfizer Inc.
- Opponent name
- Galenicum Health S.L.U.
Teva Pharmaceutical Industries Ltd.
Generics (UK) Ltd - Board
- 3.3.02
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 111European Patent Convention Art 113European Patent Convention Art 56European Patent Convention Art 84 1973European Patent Convention R 103(1)(a)European Patent Convention R 115(2)Rules of procedure of the Boards of Appeal 2020 Art 011Rules of procedure of the Boards of Appeal Art 15(3)
- Keywords
- Substantial procedural violation
Reimbursement of appeal fee
Remittal
Inventive step
Claims - clarity in opposition proceedings - Catchword
- -
- Cited cases
- G 0003/14
- Citing cases
- -
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The patent is revoked.